Bioidentical Hormones and Weight Loss

The direct answer is that hormone therapy is not a weight-loss treatment, and a clinic presenting it as one is selling something. No hormone preparation is approved for weight loss, and prescribing hormones for that purpose would mean treating a complaint rather than a diagnosis. What is true, and more useful, is that several hormone deficiencies make weight and body composition materially harder to manage — and that those deficiencies are diagnosable, measurable, and treatable on their own merits.

The research on this question is less dramatic in both directions than the marketing suggests. A Cochrane systematic review of hormone therapy in postmenopausal women found no evidence that hormone therapy causes the weight gain many women fear from it. A 2006 meta-analysis published in Diabetes, Obesity and Metabolism, pooling randomized trials of postmenopausal hormone therapy, reported reductions in abdominal fat and improvements in insulin resistance — a shift in where fat sits and how the body handles glucose rather than a reliable drop on the scale. And The Menopause Society, in its 2022 hormone therapy position statement, does not list weight loss among the indications for treatment. Taken together: hormone therapy does not make you gain weight, it can change body composition and metabolic markers, and it is not a weight-loss drug.

That distinction is the whole point of this page. The clinical principles behind the treatment itself — what “bioidentical” means, how formulations are chosen, how dosing is monitored — are set out on our bioidentical hormone replacement therapy page. What follows here is narrower: what actually changes about body composition in midlife, which hormones get measured when weight is the complaint that brought you in, and how to tell a genuine hormonal obstacle from a story that simply sounds like one.

The first correction worth making is that the scale and the body are describing two different things. In the Study of Women's Health Across the Nation, the large longitudinal cohort of midlife women whose body-composition findings were published in JCI Insight in 2019, the rate of weight gain did not accelerate as women crossed the menopausal transition. What did change was the composition of that weight: fat mass gain accelerated in the years bracketing the final menstrual period while lean mass declined over the same window. A woman whose weight has been flat for three years can therefore have meaningfully more fat and less muscle than she did at the start of them — which is exactly the experience of clothes fitting differently while the number holds steady.

Estrogen is the main reason the distribution shifts rather than only the amount. As estradiol falls, fat storage moves from the hips and thighs toward the abdomen, and the visceral fat that accumulates there is metabolically active in a way that subcutaneous fat is not — a pattern documented longitudinally by Lovejoy and colleagues in the International Journal of Obesity. The evidence behind estrogen therapy itself, including the delivery-route decision and what the Women's Health Initiative did and did not show, is covered on our estrogen replacement therapy page. For the full account of the midlife research — including what it means for exercise and protein intake — see our guide to why weight changes during menopause.

Men meet a slower version of the same problem from a different direction. Testosterone supports lean muscle mass, and muscle is the tissue that does most of the resting energy consumption; as testosterone declines, lean mass is harder to hold. Abdominal fat also contains the aromatase enzyme that converts testosterone to estradiol, so accumulated fat can push a man's testosterone lower and his estradiol higher at the same time — a loop that tends to tighten rather than resolve on its own. That axis is evaluated through our testosterone replacement therapy and BHRT for men programs; the female counterpart is our BHRT for women page.

One popular explanation deserves to be set aside. The large analysis of total energy expenditure published in Science in 2021 by Pontzer and colleagues found that energy expenditure, once adjusted for body size and composition, is comparatively stable from roughly age 20 to age 60 and declines later than most people assume. So the common account — "my metabolism collapsed at 45" — is usually not the mechanism. The loss of lean tissue, the redistribution of fat, disrupted sleep, and a reduced total activity level are doing more of the work, and each of those has something that can be done about it.

A weight complaint is not one question. It is six or seven questions that happen to produce the same symptom, and the only way to tell them apart is to measure. Dr. Riegel orders the full panel at baseline rather than testing one hormone at a time, because the interactions are where the answer usually sits.

Thyroid. The thyroid sets the pace, and it is the first thing worth excluding — measured as free T3, free T4, and antibodies rather than TSH alone, since a TSH inside the reference range does not settle the question. Honesty matters here too: the American Thyroid Association notes that the weight gain attributable to hypothyroidism is usually modest and consists substantially of salt and water rather than fat, so correcting a thyroid deficiency rarely produces dramatic weight loss by itself. What it does do is remove an obstacle, along with the fatigue and cold intolerance that came with it. Treatment is through our thyroid hormone therapy program.

Cortisol. Sustained cortisol elevation promotes central fat storage, interferes with the conversion of T4 to the active T3, and raises blood glucose independently of diet. Early-morning cortisol and DHEA-S are part of the baseline panel, and patients whose results point that direction are worked up through our adrenal fatigue evaluation, which is deliberately candid about what that popular label does and does not mean and about which genuine adrenal conditions have to be excluded first.

Testosterone, in both sexes. This is the hormone most directly tied to lean mass, and the one most often missing from a woman's panel. Diagnosis follows a standard rather than a hunch: the Endocrine Society's testosterone guideline requires consistent symptoms together with an unequivocally low morning testosterone confirmed on more than one occasion, read alongside free testosterone and SHBG. The guideline does not endorse testosterone as a treatment for obesity, and neither does this clinic.

Estradiol and progesterone. Beyond fat distribution, these two drive the sleep and mood changes that quietly wreck adherence to any eating or training plan. Progesterone is commonly the first to fall in perimenopause, because cycles stop ovulating reliably well before estrogen production ends, and its loss shows up as 3:00 AM waking and new anxiety long before anything appears on a scale. Both are covered in depth on our progesterone therapy and menopause treatment pages.

Insulin, glucose, and the metabolic markers. Fasting glucose, HbA1c, insulin, and a lipid panel are not hormones this practice replaces, but they change what the plan should be. Insulin resistance makes fat loss harder in a way that no amount of discipline overrides, and it frequently travels with the hormonal changes above rather than separately from them. Vitamin D, ferritin and iron studies, a complete blood count, and a full metabolic panel round out the baseline, because a fair share of what patients describe as a metabolic problem turns out to be a treatable deficiency producing fatigue. Where the testing points to several contributors at once rather than one, that broader picture is the subject of our hormone imbalance evaluation.

A page on this subject is only worth reading if it is as clear about the limits as about the possibilities, so here they are plainly.

Hormone therapy is not an appetite suppressant, a metabolic accelerator, or a substitute for the medications that are actually approved for weight management. It is prescribed for a documented hormone deficiency. Improved body composition is among the things that may follow when such a deficiency is corrected — it is not the indication being treated, and it is not promised.

The professional guidance is explicit on this point for both sexes. The 2019 global consensus position statement on testosterone therapy for women, endorsed by eleven professional bodies including The Menopause Society and the Endocrine Society, concluded that the only indication supported by adequate evidence is hypoactive sexual desire disorder in postmenopausal women, and that the data are insufficient to recommend testosterone for any other symptom — body composition included. On the male side, the Endocrine Society guideline cited above sets a diagnostic bar that a man with abdominal weight gain and otherwise normal testosterone will not clear, and that is the correct outcome rather than an obstacle to work around.

Nor does hormone therapy replace the fundamentals. Adequate protein, resistance training that gives the body a reason to keep the muscle it has, and sleep of sufficient length and quality are doing more for body composition in midlife than any prescription, and correcting a hormone deficiency mostly makes them effective again rather than unnecessary. Sleep in particular is worth treating as a metabolic variable rather than a lifestyle preference — it is addressed through our sleep management program. And because an honest conversation runs both ways, the risks and adjustment-period effects of hormone therapy are set out in full in our guide to the side effects of hormone replacement therapy.

Finally, you will not find a number on this page. No pounds, no percentages, no before-and-after timelines. Any clinic quoting you a figure for weight loss from hormone therapy is quoting a figure it cannot support.

The patients for whom this evaluation is most productive share a recognizable pattern. Weight or body composition has changed without a corresponding change in habits, or the habits that used to work have stopped working. The change is not alone — it arrived alongside fatigue, broken sleep, low mood or new anxiety, brain fog, loss of libido, or a drop in training capacity. The timing coincides with perimenopause, with the postmenopausal years, with a gradual male decline, or with a surgical or medical event that cut hormone production abruptly. And genuine effort is already in place, which is what makes the lack of response informative rather than ambiguous.

The patients for whom it is least productive are also worth naming. If weight is the only complaint, the rest of the picture is unremarkable, and the laboratory work comes back clean, the honest answer is that there is no hormonal deficiency to treat — and you will be told that rather than offered a prescription anyway. That answer is a legitimate outcome of an evaluation, not a failed one.

Some patients should not begin systemic hormone therapy at all, or should not begin it before further evaluation. Unexplained vaginal bleeding, a current or past estrogen-sensitive cancer, active or prior venous thromboembolism or a known clotting disorder, prior stroke or heart attack, active liver disease, and pregnancy are circumstances in which systemic estrogen is contraindicated or has to be reconsidered, per guidance from the American College of Obstetricians and Gynecologists and The Menopause Society; the male contraindication list is set out on our BHRT for men page. Screening for each of these is part of why the first appointment is thorough rather than quick.

The first appointment is an evaluation, not a treatment visit. Dr. Riegel takes a full history: when the change in weight or body composition began and how it has progressed, what has already been tried and for how long, cycle pattern or date of the final period, surgical and medical history, medications, sleep, training, and the other symptoms that arrived alongside it. Weight history is treated as clinical information rather than a character assessment, which for many patients is a departure from how the subject has been handled elsewhere.

He then orders the comprehensive panel described above and reviews the results with you in plain language — what is low, what is out of balance with what, and, importantly, what the findings do not explain. If hormone therapy is indicated, the protocol is designed from there: which hormones, at what strengths, by which route, with the progestogen component built in for any woman with a uterus. Follow-up laboratory work confirms where levels actually landed, and dosing is adjusted against both the numbers and how you report feeling, because the two do not always move together.

The office is at 4975 Preston Park Blvd, Suite 840, Plano, TX 75093, near Preston Road and Park Boulevard, with appointment hours Monday through Thursday, 10:00 AM to 4:00 PM. Costs are discussed openly once an actual protocol exists to price rather than a hypothetical one; our guide to what hormone therapy costs explains the factors involved and how insurance typically treats consultations, laboratory work, and compounded prescriptions. Patients travel in from Frisco, McKinney, Allen, Richardson, Dallas, and across North Texas, and many established patients handle follow-up through our telehealth program with laboratory draws arranged near home.

Response varies with which hormones were deficient, how long they had been deficient, the delivery route, and everything else going on in your health — so the useful answer is about order rather than dates. Sleep and mood tend to register change earliest. Energy and training capacity follow, which is the point at which most patients can actually do the resistance work that body composition depends on. Changes in body composition come last and most gradually, because they are built out of that restored capacity rather than handed over by the prescription.

That sequence is worth understanding before you start, because the patients who do best are the ones who were not expecting the scale to move in week two. Our guide to how long hormone therapy takes to work goes through the timeline symptom by symptom, and our article on weight loss and bioidentical hormone therapy covers how each of the individual hormones influences metabolism. What makes the difference is an accurate diagnosis at the start, a protocol matched to the individual, and follow-through on the monitoring — the same three things that decide the outcome of any hormone program.